Introduction

For many patients diagnosed with EGFR-mutated non-small cell lung cancer (NSCLC), receiving a prescription for Osimertinib is only the beginning of their journey. In several countries, the medicine may not yet be commercially available, may face supply shortages, or may be beyond the financial reach of many patients.

Over the years, CBMeds, a division of Curiance Biotech, has supported patients and healthcare professionals across the world in accessing prescribed oncology medicines through the Named Patient Medicine framework.

While every patient’s medical journey is unique, one common theme connects them all—the importance of timely access to treatment.

Every Patient’s Story Is Different

No two cancer journeys are exactly alike.

Some patients are newly diagnosed and searching for treatment options. Others have developed resistance to earlier EGFR therapies and require Osimertinib as the next step in their care. Many are referred by oncologists who need a reliable international supply partner.

Regardless of where patients live, one concern is shared:

“How can I access the medicine my doctor has prescribed?”

The Challenge of Global Medicine Access

Cancer medicines are not equally available around the world.

Patients may face challenges such as:

• Delayed regulatory approvals
• Limited local distribution
• Temporary shortages
• High treatment costs
• Small pharmaceutical markets
• Import restrictions

These challenges can create uncertainty at a time when patients need treatment without unnecessary delays.

A Global Support Network

Over the past several years, CBMeds has helped patients in 175 countries navigate international medicine access.

Our team works with:

• Patients
• Family members
• Oncologists
• Hospitals
• Procurement teams
• International healthcare providers

to facilitate medicine access under applicable regulatory pathways.

A Typical Patient Journey

Although every case is different, the process often follows a similar path.

Step 1: Consultation with an Oncologist

The patient’s treating oncologist determines that Osimertinib is the appropriate treatment.

Step 2: Documentation

The patient provides:

• Valid prescription
• Medical records
• Required regulatory documentation

Step 3: Regulatory Review

The CBMeds regulatory team reviews the documentation to ensure compliance with the destination country’s requirements.

Step 4: Quality-Assured Sourcing

Medicines are sourced from verified manufacturers following internationally recognized quality standards.

Step 5: International Delivery

Following documentation approval, medicines are shipped with the appropriate export and customs documentation.

More Than Medicine

Accessing treatment is about much more than receiving a package.

Patients often value:

• Clear communication
• Transparent processes
• Regulatory guidance
• Responsive customer support
• Reliable delivery timelines

Providing reassurance throughout the process can make a meaningful difference during a difficult period.

Working Alongside Healthcare Professionals

CBMeds does not replace a patient’s medical team.

Treatment decisions always remain with the treating oncologist.

Our role is to support healthcare professionals by facilitating access to prescribed medicines while maintaining regulatory compliance.

Commitment to Quality

Quality remains central to every medicine supplied.

CBMeds works with manufacturers that follow internationally recognized quality standards, including WHO Good Manufacturing Practice (WHO-GMP) where applicable.

Each shipment is supported by appropriate documentation to help ensure transparency throughout the supply chain.

Why Planning Ahead Matters

International medicine access requires coordination.

Patients are encouraged to begin the process as early as possible to allow time for:

• Documentation review
• Regulatory verification
• International logistics
• Customs clearance

Early planning helps reduce the risk of treatment interruptions.

Supporting Patients Across Borders

Healthcare should not be limited by geography.

Whether patients live in Asia, Africa, Europe, the Middle East, Latin America, or elsewhere, access to prescribed treatment remains an important part of comprehensive cancer care.

CBMeds continues to work toward making international medicine access more efficient, transparent, and patient-centered.

Frequently Asked Questions

Does CBMeds provide medical advice?

No.

Treatment decisions should always be made by the patient’s treating oncologist.

CBMeds supports medicine access—not medical diagnosis or treatment recommendations.

Do patients need a prescription?

Yes.

A valid prescription from a licensed physician is generally required before any medicine can be supplied.

How many countries does CBMeds support?

CBMeds has experience supporting patients in 175 countries, subject to local regulations and applicable medicine access pathways.

How long does international delivery usually take?

Delivery timelines vary by destination and documentation requirements.

Many shipments are completed within approximately 15–20 working days after documentation is finalized.

Is every country the same?

No.

Each country has its own regulatory requirements for importing medicines.

CBMeds reviews each request individually to help ensure compliance.

Why Patients Trust CBMeds

Patients and healthcare professionals choose CBMeds because of our commitment to:

✅ Regulatory compliance

✅ Transparent communication

✅ Quality-assured sourcing

✅ Global patient support

✅ International documentation assistance

✅ Reliable logistics coordination

Our focus is on helping eligible patients access prescribed oncology medicines through established legal pathways.

Final Thoughts

Behind every medicine request is a person, a family, and a healthcare team working toward the same goal—continuity of treatment.

While every patient’s experience is unique, timely access to prescribed medicines remains one of the most important aspects of cancer care.

Through the Named Patient Medicine framework, CBMeds, a division of Curiance Biotech, continues to support patients and healthcare professionals worldwide with responsible medicine access, regulatory expertise, and patient-centered service.

Because when treatment matters, access matters too.

Medical Disclaimer

This article is intended for educational purposes only and should not replace professional medical advice. Patients should always consult their treating oncologist regarding diagnosis, treatment, and medicine selection.